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Abstract
Background: Acquired hemophilia A (AHA) is a rare bleeding disorder caused by an autoantibody to coagulation 
factor (F) VIII. It is characterized by soft tissue bleeding in patients without a personal or family history of bleeding. 
Bleeding is variable, ranging from acute, life-threatening hemorrhage, with 9-22% mortality, to mild bleeding that 
requires no treatment. AHA usually presents to clinicians without prior experience of the disease, therefore diagnosis is 
frequently delayed and bleeds under treated.
Methods: Structured literature searches were used to support expert opinion in the development of 
recommendations for the management of patients with AHA.
Results: Immediate consultation with a hemophilia center experienced in the management of inhibitors is essential to 
ensure accurate diagnosis and appropriate treatment. The laboratory finding of prolonged activated partial 
thromboplastin time with normal prothrombin time is typical of AHA, and the diagnosis should be considered even in 
the absence of bleeding. The FVIII level and autoantibody titer are not reliable predictors of bleeding risk or response to 
treatment. Most patients with AHA are elderly; comorbidities and underlying conditions found in 50% of patients often 
influence the clinical picture. Initial treatment involves the control of acute bleeding with bypassing agents. 
Immunosuppressive treatment to eradicate the FVIII inhibitor should be started as soon as the diagnosis is confirmed 
to reduce the time the patient is at risk of bleeding.
Conclusions: These recommendations aim to increase awareness of this disorder among clinicians in a wide range of 
specialties and provide practical advice on diagnosis and treatment.
Background
Acquired hemophilia A (AHA) is a bleeding disorder
caused by an autoantibody to factor VIII [1-4]. It must be
distinguished from congenital hemophilia, which is an
inherited disorder caused by mutations in the FVIII gene
that presents at a young age and is characterized by a dis-
tinct bleeding phenotype. AHA has an estimated inci-
dence of 1.5/million/year and predominantly affects older
patients [5-7]. The disorder presents with bleeding, rang-
ing from life- and limb-threatening to mild in patients
with no personal or family history of bleeding, and has a
high mortality, estimated at between 9-22% [5,8].
Patients usually present to physicians who are not spe-
cialists in the field and have not previously managed a
case, typically geriatricians, obstetricians, rheumatolo-
gists, oncologists, emergency physicians, intensive care
physicians or surgeons as well as hematologists. Lack of
familiarity with the disorder may lead to delayed diagno-
sis and suboptimal treatment, therefore immediate con-
sultation with a hemophilia centre experienced in the
management of inhibitors is required, irrespective of the
clinical features at presentation [9,10]. The clinical phe-
notype does not correlate with the factor VIII level or
inhibitor titer [1,5], and patients remain at risk of sponta-
neous, life-threatening bleeding until the inhibitor has
been eradicated [5], even if the initial presentation is
a s s o c i a t e d  w i t h  m i l d  o r  n o  b l e e d i n g .  T h e  a g e  o f  t h e
patients and associated comorbidities [11] often influ-
ence the clinical phenotype and the risk of treatment-
induced side effects [1].
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There is no high-level evidence to support management
recommendations for patients with AHA. Some data
generated in patients with congenital hemophilia can be
used to support treatment decisions, however, most
treatment recommendations rely on the clinical experi-
ence of physicians who have managed patients with the
disorder [10]. This guideline is intended to increase the
awareness of this rare but often fatal disorder among
health care professionals to whom patients with AHA
usually present. Clinicians who require more detailed
management guidelines are referred to other publications
[10,12].
Methods
Literature searches were performed using the indexed
online databases MEDLINE/PubMed using the terms
"acquired h(a)emophilia", "acquired factor VIII inhibitors,
"acquired inhibitors" and "h(a)emophilia with inhibitors".
The full manuscripts from relevant abstracts were
retrieved and supplemented by literature from the
authors' own libraries. Approximately 150 articles were
retrieved and distributed to the author group. The manu-
script was written by the authors, coordinated and sup-
ported by Physicians World Europe GmbH, Mannheim,
Germany. Recommendations were formulated according
to the method of Guyatt et al. [13], where "we recom-
mend" represents a strong (Grade 1) recommendation
and "we suggest" a weak (Grade 2) recommendation.
Because no high or medium-level evidence exists to sup-
port management recommendations, the literature cited
was not graded according to level of evidence. A parallel
manuscript for specialist physicians was also developed
[12].
The authors comprise an independent, international
medical collaboration with expertise in the field of AHA.
The need for increased awareness of the disorder and
practice-based guidelines was initially suggested by one
member of the author group (CK). The group's activities
were funded by unrestricted educational grants from
Novo Nordisk Health Care AG, Zurich, Switzerland, a
company that commercializes recombinant factor VIIa
(NovoSeven®), an agent manufactured by Novo Nordisk
A/S, Bagsvaerd, Denmark and used to treat bleeding in
AHA.
Results and Discussion
Diagnosis
Clinical presentation
Patients with AHA tend to be elderly, with a median age
of 77 years [11]. The incidence per million per year
increases with age from 0.3 in 16-64 year olds to 9 in 65-
84 year olds and 15 in those aged 85 and older [5].
Patients with AHA present with a bleeding pattern that is
distinct from congenital hemophilia. Severity in congeni-
tal hemophilia can be predicted from the factor VIII level,
and patients predominantly experience hemarthroses,
trauma-induced muscle bleeds and other soft tissue
bleeds. AHA patients typically present with widespread
subcutaneous bleeds (seen in 80% of cases) and other soft
tissue and mucosal bleeding such as muscle hematoma,
urinogenital tract bleeding (including post partum) and
other mucosal sites. Compartment syndromes associated
with neurovascular injury are also seen, however hemar-
throses are uncommon (Tables 1 &2). Bleeds in AHA are
often spontaneous, and the severity does not correlate
with the factor VIII level [3] or strength of the inhibitor.
Severe bleeding following invasive procedures is almost
inevitable, and venipuncture commonly results in exten-
sive subcutaneous bleeding. Fatal hemorrhage occurs in
about 9-22% of cases [5,8]. In contrast, mild bleeding,
requiring no haemostatic treatment, is seen in about 30%
of cases [1,5,8,14,15] (Figure 1). Patients occasionally
present with abnormal routine blood tests without clini-
cal evidence of bleeding.
Patients remain at risk of fatal bleeding until the inhibi-
tor has been eradicated, even if they initially present with
mild or no bleeding [5]. Early hemorrhagic deaths, within
the first week, may result from gastrointestinal or lung
bleeding, whereas later deaths are predominantly due to
soft tissue bleeding such as intracranial and retroperito-
neal bleedings [5].
In about half of patients, an underlying condition is
observed (Table 3). Autoimmune diseases, including
rheumatoid arthritis and systemic lupus erythematosus,
polymyalgia rheumatica, malignancies, dermatologic dis-
ease (especially pemphigoid) and pregnancy are common
[5,8,14]. Associated medical conditions and treatment
may contribute to the clinical presentation and response
to treatment.
We recommend that physicians managing a patient
with suspected or confirmed acquired hemophilia A,
with or without bleeding, consult a hemophilia centre
with expertise in managing inhibitors as soon as pos-
sible.
AHA requires specialist clinical and laboratory exper-
tise and facilities for diagnosis and treatment [9,10].
Transfer to a specialist centre is often appropriate. If con-
sultation with or transfer to a hemophilia centre is not
Table 1: Characteristic symptoms associated with acquired 
hemophilia.
- Acute onset of severe and life-threatening bleeding or 
widespread subcutaneous bleeds
- Bleeding sites atypical of congenital hemophilia
- High mortality with both early and late deaths
- Presence of underlying diseases and conditions
- Advanced ageCollins et al. BMC Research Notes 2010, 3:161
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immediately possible then investigation and treatment
should be initiated while a liaison is being established.
Laboratory investigation
We recommend that a diagnosis of acquired hemo-
philia A be considered in all patients with recent onset
of bleeding and/or an unexplained prolonged acti-
vated partial thromboplastin time with a normal pro-
thrombin time.
We suggest use of an algorithm such as that shown
in Figure 2 for the differential diagnosis of an isolated
prolonged activated partial thromboplastin time
(aPTT).
The diagnosis of AHA is suggested by the clinical pic-
ture and confirmed by laboratory investigation. First-line
investigations for a patient with unexplained bleeding
include a full blood count to assess platelet number and a
coagulation screen. The typical finding in patients with
AHA is a prolonged aPTT with a normal prothrombin
time (PT).
Investigation of an isolated prolonged activated partial 
thromboplastin time
A prolonged aPTT with a normal PT may be due to a
deficiency of one of the intrinsic coagulation factors
(FVIII, IX, XI or XII) or indicate the presence of an inhib-
itor. An inhibitor may be against one of the intrinsic fac-
tors, most commonly FVIII, but may also be a lupus
anticoagulant. Tests for a lupus anticoagulant will be nor-
mal in the presence of a FVIII inhibitor, but a lupus anti-
coagulant may lead to artefactually low factor VIII levels
and therefore mimic AHA [16].
Irrespective of the presence or absence of bleeding, an
isolated prolonged aPTT outside the normal range
should be investigated further . If a patient has bleeding
suggestive of AHA further investigation is required even
if the aPTT is normal. Some prolonged aPTTs are clini-
cally insignificant but must be adequately investigated to
exclude an intrinsic factor deficiency or an inhibitor
before this conclusion can be drawn.
Mixing tests
To differentiate between an inhibitor and a factor defi-
ciency, mixing studies with normal plasma are used. In
these studies patient plasma is mixed with pooled normal
plasma in a ratio of 1:1. If the patient plasma has a pro-
longed aPTT secondary to a deficiency of a clotting factor
then the normal plasma will provide the missing factor
and the aPTT will be corrected to normal. If on the other
hand a patient has an inhibitor to factor VIII, then the
factor VIII in the normal plasma will be inhibited and the
aPTT will not correct. Failure of normal plasma to cor-
rect the aPTT by more than 50% is usually taken as evi-
dence that an inhibitor is present [17], although in some
laboratories other definitions are used, and there is no
international consensus. FVIII inhibitors, however, are
time- and temperature-dependent because the inhibitor
does not inhibit the factor VIII in the normal plasma
immediately. Therefore, mixing studies must be incu-
Table 2: The distribution of bleeding symptoms in two cohorts of patientsa with AHA.
Type of bleeding Collins et al. 2007 [5]
(%)
Morrison et al. 1993 [14]
(%)
N = 172 N = 65
Subcutaneous/skin 81 23
Muscle 45 32
Subcutaneous only 24
Gastrointestinal/intrabdominal 23 14
Genital urinary 9 18
Retroperitoneal/thoracic 9 5
Other 9 23
Post-operative 11
Joint 7 2
None 4
Intracranial hemorrhage 3
Fatal 9
No haemostatic treatment required 34
aIn the study by Collins et al. [5] all bleeds at presentation were recorded. In the study by Morrison et al. [14] bleeds requiring treatment were 
recorded. The studies are therefore not directly comparable.Collins et al. BMC Research Notes 2010, 3:161
http://www.biomedcentral.com/1756-0500/3/161
Page 4 of 8
bated for 1-2 h at 37°C [10,18]. A mixing study performed
without incubation for 1-2 hours or at a lower tempera-
ture may result in correction of the aPTT and the diagno-
sis of AHA potentially missed. Correction of the aPTT
with normal plasma does not exclude a FVIII inhibitor ,
and if the clinical picture is suggestive of AHA, further
investigation is warranted. If mixing tests are compatible
with an inhibitor, or the clinical picture is suggestive of
AHA, the sample should be urgently referred to a special-
ist hemostasis laboratory for further investigation by
Bethesda assay to measure the strength of the factor VIII
inhibitor [19].
Treatment
The principles of treating AHA are to control bleeding,
avoid procedures that may induce bleeds, initiate immu-
Figure 1 Extensive subcutaneous ecchymoses of the limbs, thorax and abdomen.
C
A B
D
Table 3: Disease states associated with acquired hemophilia.
Green, 1981
[8]
Morrison, 1993 [14] Collins, 2007 [5]
N 215 65 150
Idiopathic (%) 46 55 63
Collagen, vascular, and other autoimmune diseases (%) 18 17 17
Malignancy (%) 7 12 15
Skin diseases (%) 5 2 3
Possible drug reaction (%) 6 3 0
Pregnancy (%) 7 11 2Collins et al. BMC Research Notes 2010, 3:161
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nosuppression to eradicate the inhibitor and treat any
underlying disease [3,4,9,10,20].
We recommend that invasive diagnostic or thera-
peutic procedures not be undertaken unless essential
and cannot be delayed. Invasive procedures should be
undertaken at a hemophilia centre experienced in the
treatment of inhibitors.
Patients with AHA should not be subjected to invasive
procedures, unless these are essential and cannot be
delayed, because uncontrollable bleeding may result from
even minor procedures. Venipuncture, the placement of a
venous cannula and measurement of blood pressure may
also lead to severe bleeding and should be kept to a mini-
mum. Lumbar puncture should not be performed with-
out haemostatic cover. Intramuscular injections are
contraindicated. Unavoidable invasive procedures such as
the placement of central lines, arterial puncture for blood
gas assessment or lumbar puncture should be performed
under cover of a bypassing agent.
Treatment of hemorrhage
W e  r e c o m m e n d  t h a t  b l e e d i n g  e p i s o d e s  i n  p a t i e n t s
with AHA be treated in consultation with a hemo-
philia centre experienced in the treatment of inhibi-
tors.
Many patients require immediate treatment to control
bleeding, but not all types of bleeding require interven-
tion [5,15]. The cardiovascular comorbidities associated
with advanced age may put patients at risk of thrombotic
complications during haemostatic therapy. Factor VIII
levels or inhibitor titers are of no value in guiding anti-
hemorrhagic treatment [3,4,10].
First-line treatment of bleeding in AHA is with a
bypassing agent. The two available licensed treatments
are recombinant factor VIIa (rFVIIa, NovoSeven®) [21,22]
and the activated prothrombin complex concentrate
(aPCC) (FEIBA®; Factor VIII inhibitor bypassing activity)
[23]. The treating physician should be experienced in the
use of these products [24,25], or should transfer the
patient to a centre where this expertise is available. If
transfer is not possible, then haemostatic treatment
should not be delayed and treatment should be initiated
at standard doses while contact with a hemophilia centre
is established for advice. Standard treatment with rFVIIa
is 90 mcg/kg every 2 h until the bleed has been controlled
Figure 2 Algorithm to guide the management of patients with suspected acquired hemophilia. AH, acquired hemophilia; LA, lupus anticoag-
ulant; F, coagulation factor; aPTT, activated partial thromboplastin time.
Isolated prolonged aPTT
Mixing test
Suspect coagulation 
factor deficiency or LA
Exclude heparin contamination
Confirm aPTT
Consider anticoagulant influence
Negative personal and 
family history of 
bleeding disorder
No bleeding
Acute bleeding
Occult bleeding
Measure FVIII, IX, XI, XII
Single factor
deficiency
aPTT correction
Suspect clotting factor deficiency
37C at 0 and 2 hrs
Consult comprehensive
care hemophilia center
Tests for LA
Weak / no aPTT correction
Measure FVIII and inhibitor
Acquired hemophilia
Suspect acquired hemophilia or LA
Lupus Anticoagulant 
Time and temperature
dependent
Not time and temperature
dependent
Negative PositiveCollins et al. BMC Research Notes 2010, 3:161
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followed by further, less frequent dosing, to prevent
recurrence. FEIBA is dosed at 50-100 U/kg every 8-12 h
with a maximum dose of 200 U/kg/day until the bleed has
been controlled with additional doses to prevent recur-
rence.
Data on the efficacy of anti-hemorrhagic treatment are
retrospective and include a limited number of patients
with a wide range of conditions. Prospective randomized
clinical studies that compare the efficacy of the available
agents in AHA have not been performed and are imprac-
ticable due to the rarity and diverse clinical features of the
disorder. A prospective randomized trial of hemarthroses
in congenital hemophilia did not demonstrate any differ-
ence in efficacy between rFVIIa and FEIBA, although cri-
teria for equivalence were not met [26]. This study must
be viewed with caution in the context of AHA because,
while hemarthroses are common in congenital hemo-
philia, they are unusual in AHA. Retrospective studies
and clinical experience in AHA show that bypassing
agents are effective in about 90% of patients [22,23,26]. In
cases where one bypassing agent is ineffective, good effi-
cacy may be achieved with the alternative agent.
The use of bypassing agents in AHA is associated with
a risk of arterial thrombosis because many patients have
cardiovascular risk factors. A literature review reported
that 7% of patients treated with rFVIIa experienced a
thrombotic event [22]. The high risk of life-threatening
bleeding if bleeds are not treated early and adequately,
however, outweighs the risk of thrombosis in most situa-
tions, although large subcutaneous bleeds often require
no treatment.
Response to haemostatic therapy is usually best
assessed clinically and by measurement of the hemoglo-
bin or hematocrit. Radiological imaging sometimes plays
a role. There are no laboratory tests that have been dem-
onstrated to be useful for monitoring the efficacy of
bypassing agents. After hemostasis has been achieved,
further treatment may be required to prevent re-bleeds at
the same site.
If the level of the inhibitor is very low and no bypassing
agent is available, hemostasis can sometimes be achieved
with high doses of FVIII [27]. The response to this treat-
ment, however, is unpredictable and the use of factor VIII
should not delay the use of agents more likely to control
bleeding. Factor VIII is more efficacious when used as
part of multimodal treatment regimens that include
immunoadsorption to temporarily remove the inhibitor.
However, at the time of writing immunoadsorption col-
umns are not available in all countries, and this therapy is
available in only a few highly specialized centers [27-29].
Desmopressin (DDAVP) at a dose of 0.3 mcg/kg intra-
venously may be useful in the context of minor bleeding
episodes and very low titer inhibitors [30-33] but the use
of DDAVP should not delay the use of more effective
drugs. There is no evidence to support the use of intrave-
nous gammaglobulin as a single agent to resolve bleeding.
Treatment to eradicate the inhibitor
We recommend that all patients diagnosed with
acquired hemophilia A receive immunosuppressive
therapy immediately following diagnosis.
The risk of fatal bleeding continues until the factor VIII
antibody has been eradicated, therefore immunosuppres-
sion should be commenced in all patients as soon as the
diagnosis has been made [2]. Immunosuppression is best
undertaken in consultation with a hemophilia centre
experienced in the management of inhibitors, but if
advice is not immediately available, treatment should not
be delayed.
The optimal strategy for inhibitor eradication is
unknown. The two most common regimens are corticos-
teroids alone or corticosteroids combined with cyclo-
phosphamide (for reviews see [1,9]). Some experts
recommend the combination of steroids and cyclophos-
phamide as initial treatment, asserting that the inhibitor
is eradicated more rapidly [20]. However, the published
evidence from retrospective studies suggests that neither
strategy leads to a superior outcome [1,5,9] and the only
randomized study comparing the two regimens did not
recruit sufficient patients to be interpretable [34].
Reviews of published data and large cohorts suggest that
about 70-80% of patients achieve remission with steroids
alone or steroids combined with cyclosphosphamide but
studies have variable treatment regimens and different
definitions of endpoints and so cannot be directly com-
pared [1,5,9]. We therefore suggest that immunosuppres-
sion be initiated with either prednisolone alone at a dose
of 1 mg/kg or a combination of prednisolone and cyclo-
phosphamide (1-2 mg/kg).
The median time to remission with corticosteroid
treatment is about 5 weeks [9], however if the factor VIII
level has not started to increase and the inhibitor titer
decline after 2-3 weeks, an alternative immunosuppres-
sive regimen should be considered. If corticosteroid treat-
ment has been initiated and fails to induce remission,
commonly used strategies include the addition of cyclo-
phosphamide [1,9,10,34] or rituximab [1,7,34], although
rituximab is not licensed for this indication. Third-line
therapies include rituximab [35-37], if not already used,
o r  c o m b i n a t i o n s  o f  c y t o t o x i c  a g e n t s  o r  c y c l o s p o r i n
[38,39]. The side effects associated with these drugs must
be taken into consideration, particularly in the context of
patient age [11]. Neutropenia with subsequent infections
and sepsis have been reported and may contribute to
patient mortality [1,5,14,39-43].
Patients may be monitored on an outpatient basis,
except in the presence of bleeding or high comorbidity.
Patients should be educated about how to report relevant
symptoms and access specialist services on a 24-hourCollins et al. BMC Research Notes 2010, 3:161
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basis. Routine monitoring should include physical exami-
nation, hemogram, aPTT, FVIII activity and FVIII inhibi-
tor titer assessments. Relapse is seen in up to 20% of
patients, and prolonged follow-up is required [5]. Ele-
vated FVIII levels in AHA patients in remission are com-
mon, and appropriate prophylactic management in
thrombosis-prone patients should be considered during
high risk clinical episodes [44]. Thromboembolic risk in
general should be managed as in any other patient with-
out a history of a coagulation disorder [45], although
there are no studies into thromboprophylaxis in the con-
text of patients recovering from AHA.
Conclusions
Because AHA is a rare but often fatal disorder that usu-
ally presents to clinicians without previous experience of
the disorder there is often a delay in diagnosis and hence
under treatment. Due to the high mortality and morbid-
ity associated with this condition and the complexity of
diagnosis and treatment, immediate consultation with a
hemophilia centre experienced in the management of
inhibitors should be initiated whenever AHA, with or
without bleeding, is suspected.
The aim of these recommendations is to increase the
awareness of this disorder among health care profession-
als to whom AHA hemophilia patients are likely to pres-
ent, encourage timely referral to an experienced specialist
physician and create a standardized level of care for this
patient group.
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